Effective, clinically validated therapies for NiV infection are still lacking. Translational research, outbreak-ready clinical trial frameworks and prioritisation of promising therapeutic candidates are crucial for improving preparedness and clinical outcomes in future NiV outbreaks.
Kusuma et al. (Wed,) studied this question.